

Adenylyl cyclases (E.C. 4.6.1.1)

Overview: Adenylyl cyclase (ENSG00000000188) converts 5'-ATP to 3',5'-adenosine monophosphate and pyrophosphate. Mammalian membrane-bound adenylyl cyclases are typically made up of two clusters of six transmembrane domains separating two intracellular, overlapping catalytic domains that are the target for the nonselective activators forskolin, NKH477 (except AC9, Premont *et al.*, 1996) and G α s (the stimulatory G protein α subunit). Adenosine and its derivatives (e.g. 2',5'-dideoxyadenosine), acting through the P-site, appears to be a physiological inhibitor of adenylyl cyclase activity (Tesmer *et al.*, 2000). Three families of adenylyl cyclase are distinguishable: Ca²⁺/CaM-stimulated (AC1, AC3 and AC8), Ca²⁺-inhibitible (AC5 and AC6) and Ca²⁺-insensitive (AC2, AC4 and AC7) forms.

Nomenclature	AC1	AC2	AC3	AC4	AC5
Other names	AC I	AC II, HBCA2	AC III, olfactory type	AC IV	AC V
Ensembl ID	ENSG00000164742	ENSG00000078295	ENSG00000138031	ENSG00000129467	ENSG00000173175
Endogenous activators	Ca ²⁺ /CaM (Tang <i>et al.</i> , 1991), PKC-evoked phosphorylation (Jacobowitz <i>et al.</i> , 1993)	G $\beta\gamma$ (Taussig <i>et al.</i> , 1993), PKC-evoked phosphorylation (Chen and Iyengar, 1993; Lustig <i>et al.</i> , 1993)	Ca ²⁺ /CaM (Choi <i>et al.</i> , 1992), PKC-evoked phosphorylation (Jacobowitz <i>et al.</i> , 1993)	G $\beta\gamma$ (Gao and Gilman, 1991)	PKC-evoked phosphorylation (Kawabe <i>et al.</i> , 1994)
Endogenous inhibitors	G α i (Taussig <i>et al.</i> , 1994), G α o (Taussig <i>et al.</i> , 1994), G $\beta\gamma$ (Taussig <i>et al.</i> , 1993)	—	G α i (Taussig <i>et al.</i> , 1994), RGS2 (Sinnarajah <i>et al.</i> , 2001), CaM kinase II-evoked phosphorylation (Wayman <i>et al.</i> , 1995)	PKC-evoked phosphorylation (Zimmermann and Taussig, 1996)	G α i (Taussig <i>et al.</i> , 1994), Ca ²⁺ (Ishikawa <i>et al.</i> , 1992), PKA-evoked phosphorylation (Iwami <i>et al.</i> , 1995)
Selective inhibitors	—	—	—	—	NKY80 (Onda <i>et al.</i> , 2001)

Nomenclature	AC6	AC7	AC8	AC9
Other names	AC VI, Ca ²⁺ -inhibitible cyclase	AC VII	AC VIII	AC IX
Ensembl ID	ENSG00000174233	ENSG00000121281	ENSG00000155897	ENSG00000162104
Endogenous activators	—	PKC-evoked phosphorylation (Watson <i>et al.</i> , 1994)	Ca ²⁺ (Cali <i>et al.</i> , 1994)	—
Endogenous inhibitors	G α i (Taussig <i>et al.</i> , 1994), Ca ²⁺ (Yoshimura and Cooper, 1992), PKA-evoked phosphorylation (Chen <i>et al.</i> , 1997), PKC-evoked phosphorylation (Lai <i>et al.</i> , 1999)	—	—	Ca ²⁺ /calciurein (Paterson <i>et al.</i> , 2000)

Nitric oxide has been proposed to inhibit AC5 and AC6 selectively (Hill *et al.*, 2000), although it is unclear whether this phenomenon is of physiological significance. A soluble adenylyl cyclase has been described (ENSG00000143199, Buck *et al.*, 1999), unaffected by either G α or G $\beta\gamma$ subunits, which has been suggested to be a cytoplasmic bicarbonate (pH-insensitive) sensor (Chen *et al.*, 2000).

Abbreviations: **CaM**, calmodulin; **NKH477**, 6-(3-dimethylaminopropionyl) forskolin hydrochloride; **NKY80**, 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; **PKA**, protein kinase A or cyclic AMP-dependent protein kinase; **PKC**, protein kinase C; **RGS2**, Regulator of G-protein signalling 2 (ENSG00000116741)

Further Reading:

- BEAZELY, M.A. & WATTS, V.J. (2006). Regulatory properties of adenylate cyclases type 5 and 6: A progress report. *Eur. J. Pharmacol.*, **535**, 1–12.
- COOPER, D.M.F. (2003). Regulation and organization of adenylyl cyclases and cAMP. *Biochem. J.*, **375**, 517–529.
- COOPER, D.M.F. & CROSTHWAITE, A.J. (2006). Higher-order organization and regulation of adenylyl cyclases. *Trends Pharmacol. Sci.*, **27**, 426–431.
- HANOUNE, J. & DEFER, N. (2001). Regulation and role of adenylyl cyclase isoforms. *Annu. Rev. Pharmacol. Toxicol.*, **41**, 145–174.
- INSEL, P.A. & OSTROM, R.S. (2003). Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. *Cell. Mol. Neurobiol.*, **23**, 305–314.
- JOHNSTON, C.A. & WATTS, V.J. (2003). Sensitization of adenylate cyclase: a general mechanism of neuroadaptation to persistent activation of G $\alpha_{i/o}$ -coupled receptors? *Life Sci.*, **73**, 2913–2925.
- LINDER, J.U. (2006). Class III adenylyl cyclases: molecular mechanisms of catalysis and regulation. *Cell. Mol. Life Sci.*, **63**, 1736–1751.
- LORENZ, K., LOHSE, M.J. & QUITTERER, U. (2003). Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. *Nature*, **426**, 574–579.
- WANG, H. & STORM, D.R. (2003). Calmodulin-regulated adenylyl cyclases: cross-talk and plasticity in the central nervous system. *Mol. Pharmacol.*, **63**, 463–468.
- WATTS, V.J. & NEVE, K.A. (2005). Sensitization of adenylate cyclase by G α i/o-coupled receptors. *Pharmacol. Ther.*, **106**, 405–421.

References:

- BUCK, J. *et al.* (1999). *Proc. Natl. Acad. Sci. U.S.A.*, **96**, 79–84.
- CALI, J.J. *et al.* (1994). *J. Biol. Chem.*, **269**, 12190–12195.
- CHEN, J.Q. & IYENGAR, R. (1993). *J. Biol. Chem.*, **268**, 12253–12256.
- CHEN, Y. *et al.* (1997). *Proc. Natl. Acad. Sci. U.S.A.*, **94**, 14100–14104.
- CHEN, Y. *et al.* (2000). *Science*, **289**, 625–628.

- CHOI, E.J. *et al.* (1992). *Biochemistry*, **31**, 6492–6498.
- GAO, B.N. & GILMAN, A.G. (1991). *Proc. Natl. Acad. Sci. U.S.A.*, **88**, 10178–10182.
- HILL, J. *et al.* (2000). *Cell. Signal.*, **12**, 233–237.
- ISHIKAWA, Y. *et al.* (1992). *J. Biol. Chem.*, **267**, 13553–13557.
- IWAMI, G. *et al.* (1995). *J. Biol. Chem.*, **270**, 12481–12484.
- JACOBOWITZ, O. *et al.* (1993). *J. Biol. Chem.*, **268**, 3829–3832.
- KAWABE, J.-I. *et al.* (1994). *J. Biol. Chem.*, **269**, 16554–16558.
- LAI, H.-L. *et al.* (1999). *Mol. Pharmacol.*, **56**, 644–650.
- LUSTIG, K.D. *et al.* (1993). *J. Biol. Chem.*, **268**, 13900–13905.
- PATERSON, J.M. *et al.* (2000). *J. Neurochem.*, **75**, 1358–1367.
- PREMONT, R.T. *et al.* (1996). *J. Biol. Chem.*, **271**, 13900–13907.
- SINNARAJAH, S. *et al.* (2001). *Nature*, **409**, 1051–1055.
- TAUSSIG, R. *et al.* (1993). *J. Biol. Chem.*, **268**, 9–12.
- TAUSSIG, R. *et al.* (1994). *J. Biol. Chem.*, **269**, 6093–6100.
- TESMER, J.J. *et al.* (2000). *Biochemistry*, **39**, 14464–14471.
- WATSON, P.A. *et al.* (1994). *J. Biol. Chem.*, **269**, 28893–28898.
- WAYMAN, G.A. *et al.* (1995). *J. Biol. Chem.*, **270**, 21480–21486.
- YOSHIMURA, M. & COOPER, D.M.F. (1992). *Proc. Natl. Acad. Sci. U.S.A.*, **89**, 6716–6720.
- ZIMMERMANN, G. & TAUSSIG, R. (1996). *J. Biol. Chem.*, **271**, 27161–27166.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Amino acid hydroxylases (E.C.1.14.16.—)

Overview: The amino acid hydroxylases (monooxygenases) are iron-containing enzymes which utilise molecular oxygen and tetrahydrobiopterin as co-substrate and co-factor, respectively.

Nomenclature	L-Phenylalanine hydroxylase	L-Tryptophan hydroxylase	L-Tyrosine hydroxylase
E.C.	1.14.16.1	1.14.16.4	1.14.16.2
Preferred abbreviation	PH	TPH	TH
Other names	Phenylalanine 4-monooxygenase	Tryptophan 5-monooxygenase	Tyrosine 3-monooxygenase
Ensembl ID	ENSG00000171759	TPH1 ENSG00000129167; TPH2 ENSG00000139287	ENSG00000180176
Product	Tyrosine	5-Hydroxytryptophan	DOPA
Selective inhibitors	α -Methylphenylalanine (Greengard <i>et al.</i> , 1996), PCPA	Fenfluramine, PCPA, α -propylidopacetamide, 6-fluorotryptophan (Nicholson & Wright, 1981)	3-Chlorotyrosine, 3-iodotyrosine, α -methyltyrosine, α -propylidopacetamide

Abbreviations: DOPA, 3,4-dihydroxyphenylalanine; PCPA, 4-chlorophenylalanine

Further Reading:

DUNKLEY, P.R., BOBROVSKAYA, L., GRAHAM, M.E., VON NAGY-FELSOBUKI, E.I. & DICKSON, P.W. (2004). Tyrosine hydroxylase phosphorylation: regulation and consequences. *J. Neurochem.*, **91**, 1025–1043.

FITZPATRICK, P.F. (2003). Mechanism of aromatic amino acid hydroxylation. *Biochemistry.*, **42**, 14083–14091.

FLATMARK, T. (2000). Catecholamine biosynthesis and physiological regulation in neuroendocrine cells. *Acta Physiol. Scand.*, **168**, 1–17.

KOBAYASHI, K. & NAGATSU, T. (2005). Molecular genetics of tyrosine 3-monooxygenase and inherited diseases. *Biochem. Biophys. Res. Commun.*, **338**, 267–270.

MISU, Y., KITAHAMA, K. & GOSHIMA, Y. (2003). L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system. *Pharmacol. Ther.*, **97**, 117–137.

ZHANG, X., BEAULIEU, J.M., GAINETDINOV, R.R. & CARON, M.G. (2006). Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. *Cell Mol. Life Sci.*, **63**, 6–11.

References:

GREENGARD, O. *et al.* (1976). *Science*, **192**, 1007–1008.

NICHOLSON, A.N. & WRIGHT, C.M. (1981). *Neuropharmacology*, **20**, 335–339.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Cyclooxygenase (E.C. 1.14.99.1)

Overview: Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor: oxygen oxidoreductase) activity, catalyses the formation of PG G₂ from arachidonic acid. Hydroperoxidase activity inherent in the enzyme catalyses the formation of PGH₂ from PGG₂. COX-1 and -2 can be nonselectively inhibited by ibuprofen, ketoprofen, naproxen, indometacin and paracetamol (acetaminophen).

Nomenclature	COX-1	COX-2
Other names	Prostaglandin G ₂ /H ₂ synthase-1	Prostaglandin G ₂ /H ₂ synthase-2
Ensemble ID	ENSG00000095303	ENSG00000073756
Substrates	Arachidonic acid	Arachidonic acid, docosahexaenoic acid
Selective inhibitors	FR122047 (7.5, Ochi <i>et al.</i> , 2000), valeroylsalicylate (Bhattacharyya <i>et al.</i> , 1995)	Diclofenac (6.7), celecoxib (5.1), rofecoxib (4.3), valdecoxib, parecoxib, etoricoxib, lumiracoxib

Abbreviations: **FR122047**, 1-([4,5-bis{methoxyphenyl}-2-thazolylcarbonyl)-4-methyl)piperazine hydrochloride

Further Reading:

- BAKHLE, Y.S. (2001). COX-2 and cancer: a new approach to an old problem. *Br. J. Pharmacol.*, **134**, 1137–1150.
- CATELLA-LAWSON, F., REILLY, M.P., KAPOOR, S.C., CUCCHIARA, A.J., DEMARCO, S., TOURNIER, B., VYAS, S.N. & FITZGERALD, G.A. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. *N. Engl. J. Med.*, **345**, 1809–1817.
- DE GAETANO, G., DONATI, M.B. & CERLETTI, C. (2003). Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. *Trends Pharmacol. Sci.*, **24**, 245–252.
- DUBOIS, R.N., ABRAMSON, S.B., CROFFORD, L., GUPTA, R.A., SIMON, L.S., VAN DE PUTTE, L.B.A. & LIPSKY, P.E. (1998). Cyclooxygenase in biology and disease. *FASEB J.*, **12**, 1063–1073.
- FIORUCCI, S., MELI, R., BUCCI, M. & CIRINO, G. (2001). Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? *Biochem. Pharmacol.*, **62**, 1433–1438.
- FITZGERALD, G.A. & PATRONO, C. (2001). The coxibs, selective inhibitors of cyclooxygenase-2. *N. Engl. J. Med.*, **345**, 433–442.
- FITZGERALD, G.A. (2003). COX-2 and beyond; approaches to prostaglandin inhibition in human disease. *Nat. Rev. Drug Disc.*, **2**, 879–890.
- GARG, R., KURUP, A., MEKAPATI, S.B. & HANSCH, C. (2003). Cyclooxygenase (COX) inhibitors: a comparative QSAR study. *Chem. Rev.*, **103**, 703–732.
- GUPTA, R.A. & DUBOIS, R.N. (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. *Nat. Rev. Cancer*, **1**, 11–21.
- HAWKEY, C.J. & LANGMAN, M.J. (2003). Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. *Gut*, **52**, 600–608.
- HINZ, B. & BRUNE, K. (2002). Cyclooxygenase-2–10 years later. *J. Pharmacol. Exp. Ther.*, **300**, 367–375.
- HWANG, D. (2001). Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through toll-like receptor 4-derived signaling pathways. *FASEB J.*, **15**, 2556–2564.
- MARCUS, A.J., BROEKMAN, M.J. & PINSKY, D.J. (2002). COX inhibitors and thromboregulation. *N. Engl. J. Med.*, **347**, 1025–1026.
- MARNETT, L.J. & DUBOIS, R.N. (2002). COX-2: a target for colon cancer prevention. *Annu. Rev. Pharmacol. Toxicol.*, **42**, 55–80.
- MATZ, R.L., SCHOTT, C., STOCLET, J.C. & ANDRIANTSITOHAINA, R. (2000). Age-related endothelial dysfunction with respect to nitric oxide, endothelium-derived hyperpolarizing factor and cyclooxygenase products. *Physiol. Res.*, **49**, 11–18.
- MITCHELL, J.A. & WARNER, T.D. (2006). COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. *Nat. Rev. Drug Discov.*, **5**, 75–86.
- MORITA, I. (2002). Distinct functions of COX-1 and COX-2. *Prostaglandins Other Lipid Mediat.*, **68–69**, 165–175.
- PATRONO, C., PATRIGNANI, P. & GARCIA RODRIGUEZ, L.A. (2001). Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. *J. Clin. Invest.*, **108**, 7–13.
- PRESCOTT, S.M. & FITZPATRICK, F.A. (2000). Cyclooxygenase-2 and carcinogenesis. *Biochim. Biophys. Acta*, **1470**, M69–M78.
- SERHAN, C.N. & OLIW, E. (2001). Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. *J. Clin. Invest.*, **107**, 1481–1489.
- SMITH, W.L. & LANGENBACH, R. (2001). Why there are two cyclooxygenase isozymes. *J. Clin. Invest.*, **107**, 1491–1495.
- SUBBARAMAIAH, K. & DANNENBERG, A.J. (2003). Cyclooxygenase 2: a molecular target for cancer prevention and treatment. *Trends Pharmacol. Sci.*, **24**, 96–102.
- SVENSSON, C.I. & YAKSH, T.L. (2002). The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing. *Annu. Rev. Pharmacol. Toxicol.*, **42**, 553–583.
- TANABE, T. & TOHNAI, N. (2002). Cyclooxygenase isozymes and their gene structures and expression. *Prostaglandins Other Lipid Mediat.*, **68–69**, 95–114.
- TEGEDER, I., PFEILSCHIFTER, J. & GEISSLINGER, G. (2001). Cyclooxygenase-independent actions of cyclooxygenase inhibitors. *FASEB J.*, **15**, 2057–2072.
- TURINI, M.E. & DUBOIS, R.N. (2002). Cyclooxygenase-2: a therapeutic target. *Annu. Rev. Med.*, **53**, 35–57.
- WARNER, T.D. & MITCHELL, J.A. (2002). Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? *Proc. Natl. Acad. Sci. USA*, **99**, 13371–13373.

References:

- BHATTACHARYYA, D.K. *et al.* (1995). *Arch. Biochem. Biophys.*, **317**, 19–24.
- OCHI, T. *et al.* (2000). *Eur. J. Pharmacol.*, **391**, 49–54.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Decarboxylases (E.C. 4.1.1.—)

Overview: The decarboxylases generate CO₂ and the indicated products from acidic substrates, requiring pyridoxal phosphate (ADC, AADC, GAD, HDC, ODC and PSDC or pyruvate (SAMDC and PSDC) as a co-factor. The activity of ODC is regulated by the presence of an antizyme (ENSF0000002504) and an ODC antizyme inhibitor (ENSF0000002504).

Nomenclature	<i>S</i> -Adenosylmethionine decarboxylase	L-Arginine decarboxylase	L-Aromatic amino-acid decarboxylase	Glutamic acid decarboxylase
E.C.	4.1.1.50	4.1.1.19	4.1.1.28	4.1.1.15
Preferred abbreviation	SAMDC	ADC	AADC	GAD
Other names	—	Ornithine decarboxylase-like protein (Zhu <i>et al.</i> , 2004)	DOPA decarboxylase (DDC), 5-hydroxytryptophan decarboxylase	GAD1 (GAD65), GAD2 (GAD67)
Ensembl ID	ENSG00000123505	ENSG00000142920	ENSG00000132437	ENSG00000128683, ENSG00000136750
Substrate(s)	<i>S</i> -Adenosylmethionine	L-Arginine	DOPA, L-tryptophan, 5-hydroxy-L-tryptophan	L-Glutamate, L-aspartate
Product(s)	5'-Deoxyadenosyl-(3-aminopropyl) methylsulfonium	Agmatine	5-Hydroxytryptophan, dopamine	GABA
Selective inhibitors	SAM486A (8.0; Stanek <i>et al.</i> , 1993), AMA	—	Benserazide, carbidopa, 3-hydroxybenzylhydrazine, L- α -methyldopa	<i>S</i> -Allylglycine

The presence of a functional ADC activity in human tissues has been questioned (Coleman *et al.*, 2004). *S*-Allylglycine is also an inhibitor of SAMDC (Pajunen *et al.*, 1979).

Nomenclature	Histidine decarboxylase	Ornithine decarboxylase	Phosphatidylserine decarboxylase
E.C.	4.1.1.22	4.1.1.17	4.1.1.65
Preferred abbreviation	HDC	ODC	PSDC
Ensembl ID	ENSG00000140287	ENSG00000115758	ENSG00000100141
Substrate(s)	L-Histidine	L-Ornithine	Phosphatidylserine
Product	Histamine	Putrescine	Phosphatidylethanolamine
Selective inhibitors	FMH (Garbarg <i>et al.</i> , 1980)	DFMO, APA	—

Abbreviations: **AMA**, S-(5'-deoxy-5'-adenosyl)-methylthioethyl-hydroxylamine; **APA**, 1-aminooxy-3-aminopropane; **DFMO**, α -difluoromethyl-L-ornithine, also known as eflornithine; **FMH**, α -fluoromethylhistidine; **SAM**, S-adenosylmethionine; **SAM486A**, 1-guanidinoimino-2,3-dihydroindene-4-carboximidamide, also known as CGP48664

Further Reading:

BERNSTEIN, H.G. & MULLER, M. (1999). The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. *Prog. Neurobiol.*, **57**, 485–505.

CHOI, J.Y., WU, W.I. & VOELKER, D.R. (2005). Phosphatidylserine decarboxylases as genetic and biochemical tools for studying phospholipid traffic. *Anal. Biochem.*, **347**, 165–175.

MOYA-GARCIA, A.A., MEDINA, M.A. & SANCHEZ-JIMENEZ, F. (2005). Mammalian histidine decarboxylase: from structure to function. *Bioessays*, **27**, 57–63.

OHTSU, H. & WATANABE, T. (2003). New functions of histamine found in histidine decarboxylase gene knockout mice. *Biochem. Biophys. Res. Commun.*, **305**, 443–447.

PEGG, A.E. (2006). Regulation of ornithine decarboxylase. *J. Biol. Chem.*, **281**, 14529–14532.

PONS, R., FORD, B., CHIRIBOGA, C.A., CLAYTON, P.T., HINTON, V., HYLAND, K., SHARMA, R. & DE, V. (2004). Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. *Neurology*, **62**, 1058–1065.

SMITH, K.J. & SKELTON, H. (2006). α -Difluoromethylornithine, a polyamine inhibitor: its potential role in controlling hair growth and in cancer treatment and chemo-prevention. *Int. J. Dermatol.*, **45**, 337–344.

VANCE, J.E. & VANCE, D.E. (2004). Phospholipid biosynthesis in mammalian cells. *Biochem. Cell. Biol.*, **82**, 113–128.

References:

COLEMAN, C.S. *et al.* (2004). *Biochem. J.*, **379**, 849–855.

GARBARG, M. *et al.* (1980). *J. Neurochem.*, **35**, 1045–1052.

PAJUNEN, A.E. *et al.* (1979). *J. Neurochem.*, **32**, 1401–1408.

STANEK, J. *et al.* (1993). *J. Med. Chem.*, **36**, 2168–2171.

ZHU, M.Y. *et al.* (2004). *Biochim. Biophys. Acta*, **1670**, 156–164.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Inositol monophosphatase (E.C.3.1.3.25)

Overview: Inositol monophosphatase (IMPase, *myo*-inositol-1(or 4)-phosphate phosphohydrolase) is a magnesium-dependent homodimer which hydrolyses *myo*-inositol monophosphate to generate *myo*-inositol and phosphate. Glycerol may be a physiological phosphate acceptor. Lithium is a nonselective un-competitive inhibitor of IMPase (pK_i *ca.* 3.5, McAllister *et al.*, 1992). IMPase activity may be inhibited competitively by L690330 (pK_i 5.5, McAllister *et al.*, 1992), although the enzyme selectivity is not yet established.

Nomenclature	IMPase 1	IMPase 2
Other names	IMPA1	IMPA2
Ensembl ID	ENSG00000133731	ENSG00000141401
Rank order of affinity	Inositol 4-phosphate>inositol 3-phosphate>inositol 1-phosphate (McAllister <i>et al.</i> , 1992)	—

Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder (Sjoholt *et al.*, 1997; Yoshikawa *et al.*, 1997; Sjoholt *et al.*, 2000).

Abbreviations: L690330, 1-(4-hydroxyphenoxy)ethane-1,1-bisphosphonate

Further Reading:

IKEDA, A. & KATO, T. (2003). Biological predictors of lithium response in bipolar disorder. *Psychiatry Clin. Neurosci.*, **57**, 243–250.

LENOX, R.H. & WANG, L. (2003). Molecular basis of lithium action: integration of lithium-responsive signaling and gene expression networks. *Mol. Psychiatry*, **8**, 135–144.

PHIEL, C.J. & KLEIN, P.S. (2001). Molecular targets of lithium action. *Annu. Rev. Pharmacol. Toxicol.*, **41**, 789–813.

References:

MCALLISTER, G. *et al.* (1992). *Biochem. J.*, **284**, 749–754.

SJOHOLT, G. *et al.* (1997). *Genomics*, **45**, 113–122.

SJOHOLT, G. *et al.* (2000). *Mol. Psychiatry*, **5**, 172–180.

YOSHIKAWA, T. *et al.* (1997). *Mol. Psychiatry*, **2**, 393–397.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Lipoxygenases (E.C. 1.13.11.—)

Overview: The lipoxygenases (LOXs) are a structurally related family of nonheme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. In humans, the 5*S*-(arachidonate : oxygen 5-oxidoreductase), 12*R*-(arachidonate 12-lipoxygenase, 12*R*-type), 12*S*-(arachidonate : oxygen 12-oxidoreductase), and 15*S*-(arachidonate : oxygen 15-oxidoreductase). LOXs oxygenate arachidonic acid in different positions along the carbon chain and form the corresponding 5*S*-, 12*S*-, 12*R*-, or 15*S*-hydroperoxides, respectively. The epidermal lipoxygenase 3 (E-LOX) metabolises the product from the 12*R*-lipoxygenase (12*R*-HPETE) to a specific epoxyalcohol compound (Yu *et al.*, 2003). Some general LOX inhibitors are NDGA and esculetin.

Nomenclature	5-LOX	12R-LOX	12S-LOX
E.C.	1.13.11.34	1.13.11.-	1.13.11.31
Other names	ALOX5	ALOX12B	ALOX12, platelet-type 12-lipoxygenase
Ensembl ID	ENSG00000012779	ENSG00000179477	ENSG00000108839
Substrates	Arachidonic acid	Methyl arachidonate	Arachidonic acid
Activators	FLAP	—	—
Selective inhibitors	Zileuton, CJ13610 (Fischer <i>et al.</i> , 2004)	—	—

Nomenclature	15-LOX-1	15-LOX-2	E-LOX
E.C.	1.13.11.33	1.13.11.33	1.13.11.-
Other names	ALOX15, arachidonate ω -6 lipoxygenase	ALOX15B	Epidermis type LOX 3
Ensembl ID	ENSG00000161905	ENSG00000179593	ENSG00000179148
Substrates	Linoleic acid, arachidonic acid	Arachidonic acid	12 <i>R</i> -HPETE

An 8-LOX (EC 1.13.11.40, arachidonate:oxygen 8-oxidoreductase) may be the mouse orthologue of 15-LOX-2 (Furstenberger *et al.*, 2002). Caffeic acid is used as a 5-lipoxygenase inhibitor, while baicalein and CDC are 12-lipoxygenase inhibitors. The specificity of these inhibitors has not been rigorously assessed with all LOX forms: baicalein, along with other flavonoids, such as fisetin and luteolin, also inhibits 15-LOX-1 (Sadik *et al.*, 2003).

Abbreviations: CDC, cinnamyl-3,4-dihydroxy- α -cyanocinnamate; **CJ13610**, 1-carboxamido-1-(3-*S*-[4-{2-methylimidazole}-thiophenyl])-4-cyclopentylether; **esculetin**, 6,7-dihydroxycoumarin; **12*R*-HPETE**, 12*R*-hydroperoxyeicosatetraenoic acid; **FLAP**, 5-lipoxygenase-activating protein, also known as MK-886-binding protein (ENSG00000132965); **NDGA**, nordihydroguaiaretic acid

Further Reading:

- BIGBY, T.D. (2002). The yin and the yang of 5-lipoxygenase pathway activation. *Mol. Pharmacol.*, **62**, 200–202.
- FIORUCCI, S., MELI, R., BUCCI, M. & CIRINO, G. (2001). Dual inhibitors of cyclooxygenase and 5-lipoxygenase? A new avenue in anti-inflammatory therapy? *Biochem. Pharmacol.*, **62**, 1433–1438.
- FUNK, C.D. & CHEN, X.S. (2000). 5-Lipoxygenase and leukotrienes. Transgenic mouse and nuclear targeting studies. *Am. J. Resp Crit. Care Med.*, **161**, S120–S124.
- FUNK, C.D., CHEN, X.S., JOHNSON, E.N. & ZHAO, L. (2002). Lipoxygenase genes and their targeted disruption. *Prostaglandins Other Lipid Mediat.*, **68–69**, 303–312.
- FUNK, C.D. & CYRUS, T. (2001). 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. *Trends Cardiovasc Med.*, **11**, 116–124.
- KUHN, H., WALTHER, M. & KUBAN, R.J. (2002). Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. *Prostaglandins Other Lipid Mediat.*, **68–69**, 263–290.
- LOTZER, K., FUNK, C.D. & HABENICHT, A.J. (2005). The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. *Biochim. Biophys. Acta*, **1736**, 30–37.
- NIE, D. & HONN, K.V. (2002). Cyclooxygenase, lipoxygenase and tumor angiogenesis. *Cell. Mol. Life Sci.*, **59**, 799–807.
- OSHER, E., WEISINGER, G., LIMOR, R., TORDJMAN, K. & STERN, N. (2006). The 5 lipoxygenase system in the vasculature: emerging role in health and disease. *Mol. Cell. Endocrinol.*, **252**, 201–206.
- PETERS-GOLDEN, M. & BROCK, T.G. (2003). 5-Lipoxygenase and FLAP. *Prostaglandins Leukot. Essent Fatty Acids*, **69**, 99–109.
- POWELL, W.S. & ROKACH, J. (2005). Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-EETE. *Prog. Lipid Res.*, **44**, 154–183.
- RÅDMARK, O. (2002). Arachidonate 5-lipoxygenase. *Prostaglandins Other Lipid Mediat.*, **68–69**, 211–234.
- RÅDMARK, O. & SAMUELSSON, B. (2005). Regulation of 5-lipoxygenase enzyme activity. *Biochem. Biophys. Res. Commun.*, **338**, 102–110.
- WERZ, O. & STEINHILBER, D. (2005). Development of 5-lipoxygenase inhibitors – lessons from cellular enzyme regulation. *Biochem. Pharmacol.*, **70**, 327–333.
- YOSHIMOTO, T. & TAKAHASHI, Y. (2002). Arachidonate 12-lipoxygenases. *Prostaglandins Other Lipid Mediat.*, **68–69**, 245–262.

References:

- FISCHER, L. *et al.* (2004). *Br. J. Pharmacol.*, **142**, 861–868.
- FURSTENBERGER, G. *et al.* (2002). *Prostaglandins Other Lipid Mediat.*, **68–69**, 235–243.
- SADIK, C.D. *et al.* (2003). *Biochem. Pharmacol.*, **65**, 773–781.
- YU, Z. *et al.* (2003). *Proc. Natl. Acad. Sci. U.S.A.*, **100**, 9162–9167.
- ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Nitric oxide synthase (E.C. 1.14.13.39)

Overview: The nomenclature suggested by NC-IUPHAR of NOS I, II and III (see Moncada *et al.*, 1997) has not gained wide acceptance. Nitric oxide synthases (NOS, L-arginine, NADPH₂:oxygen oxidoreductase (nitric-oxide-forming)) utilise L-arginine (not D-arginine) and molecular oxygen to generate nitric oxide and L-citrulline. eNOS and nNOS isoforms are activated at concentrations of calcium greater than 100 nM, while iNOS shows higher affinity for Ca²⁺/calmodulin and thus appears to be constitutively active. All the three isoforms are homodimers and require tetrahydrobiopterin, flavin adenine dinucleotide, flavin mononucleotide and NADPH for catalytic activity. L-NAME is an inhibitor of all three isoforms, with an IC₅₀ value in the micromolar range.

Nomenclature	Endothelial NOS	Inducible NOS	Neuronal NOS
Preferred abbreviation	ENOS	iNOS	nNOS
Other names	NOS III, NOS-3, ecNOS	NOS II, NOS-2	NOS I, NOS-1, brain NOS
Ensembl ID	ENSG00000164867	ENSG00000007171	ENSG00000089250
Selective inhibitors	—	1400W (8.2, Garvey <i>et al.</i> , 1997), 2-amino-4-methylpyridine (7.4, Faraci <i>et al.</i> , 1996), PIBTU (7.3, Garvey <i>et al.</i> , 1994), NIL (5.5, Moore <i>et al.</i> , 1994), aminoguanidine (Corbett & McDaniel, 1992)	3-Bromo-7NI (6.1-6.5, Bland-Ward and Moore, 1995), 7NI (5.3, Babbedge <i>et al.</i> , 1993)

The reductase domain of NOS catalyses the reduction of cytochrome *c* and other redox-active dyes (Mayer & Hemmens, 1997). NADPH:O₂ oxidoreductase catalyses the formation of superoxide anion/H₂O₂ in the absence of arginine and tetrahydrobiopterin.

Abbreviations: **1400W**, *N*-(3-(aminomethyl) benzyl)acetamidine; **NADPH**, reduced nicotinamide adenosine dinucleotide phosphate; **7NI**, 7-nitroindazole; **NIL**, *L*-N⁶-(1-iminoethyl)lysine; **PIBTU**, 13-phenylen-bis(1,2ethanediy)bis-thiourea

Further Reading:

ALDERTON, W.K., COOPER, C.E. & KNOWLES, R.G. (2001). Nitric oxide synthases: structure, function and inhibition. *Biochem. J.*, **357**, 593–615.

CARY, S.P., WINGER, J.A., DERBYSHIRE, E.R. & MARLETTA, M.A. (2006). Nitric oxide signaling: no longer simply on or off. *Trends Biochem. Sci.*, **31**, 231–239.

DUDZINSKI, D.M., IGARASHI, J., GREIF, D. & MICHEL, T. (2006). The regulation and pharmacology of endothelial nitric oxide synthase. *Annu. Rev. Pharmacol. Toxicol.*, **46**, 235–276.

FISH, J.E. & MARSDEN, P.A. (2006). Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. *Cell. Mol. Life Sci.*, **63**, 144–162.

FORSTERMANN, U. & MUNZEL, T. (2006). Endothelial nitric oxide synthase in vascular disease: from marvel to menace. *Circulation*, **113**, 1708–1714.

OESS, S., ICKING, A., FULTON, D., GOVERS, R. & MULLER-ESTERL, W. (2006). Subcellular targeting and trafficking of nitric oxide synthases. *Biochem. J.*, **396**, 401–409.

REDINGTON, A.E. (2006). Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. *Eur. J. Pharmacol.*, **533**, 263–276.

SHAUL, P.W. (2002). Regulation of endothelial nitric oxide synthase: location, location, location. *Annu. Rev. Physiol.*, **64**, 749–774.

References:

BABBEDGE, R.C. *et al.* (1993). *Br. J. Pharmacol.*, **110**, 225–228.

BLAND-WARD, P.A. & MOORE, P.K. (1995). *Life Sci.*, **57**, PL131–PL135.

CORBETT, J.A. & MCDANIEL, M.L. (1992). *Diabetes*, **41**, 897–903.

FARACI, W.S. *et al.* (1996). *Br. J. Pharmacol.*, **119**, 1101–1108.

GARVEY, E.P. *et al.* (1997). *J. Biol. Chem.*, **272**, 4959–4963.

GARVEY, E.P. *et al.* (1994). *J. Biol. Chem.*, **269**, 26669–26676.

MAYER, B. & HEMMENS, B. (1997). *Trends Biochem. Sci.*, **22**, 477–481.

MOORE, W.M. *et al.* (1994). *J. Med. Chem.*, **37**, 3886–3888.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Phosphatidylcholine-specific phospholipase D (E.C. 3.1.4.4)

Overview: Phosphatidylcholine-specific phospholipase D (PLD, ENSF0000001451) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols, such as butanol in a transphosphatidylation reaction (Randall *et al.*, 1990).

Nomenclature	PLD1	PLD2
Other names	Choline phosphatase 1	Choline phosphatase 2
Ensembl ID	ENSG00000075651	ENSG00000129219
Endogenous activators	ARF, PIP ₂ , RhoA, PKC-evoked phosphorylation (Hammond <i>et al.</i> , 1997)	ARF, PIP ₂ (Lopez <i>et al.</i> , 1998), oleic acid (Sarri <i>et al.</i> , 2003)

A lysophospholipase D activity (ENSG00000136960, also known as ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), phosphodiesterase I, nucleotide pyrophosphatase 2, autotaxin) has been described, which not only catalyses the production of lysophosphatidic acid from lysophosphatidylcholine, but also cleaves ATP (see Goding *et al.*, 2003). Additionally, an *N*-acylethanolamine-specific phospholipase D (NAPE-PLD, ENSG00000161048) has recently been characterized, which appears to have a role in the generation of endocannabinoids/endovanilloids, including anandamide (Okamoto *et al.*, 2004). This enzyme activity appears to be enhanced by polyamines in the physiological range (Liu *et al.*, 2002) and fails to transphosphatidylate with alcohols (Petersen & Hansen, 1999).

Abbreviations: ARF, ADP-ribosylation factor; NAPE-PLD, *N*-acylethanolamine-specific phospholipase D; PIP₂, phosphatidylinositol 4,5-bisphosphate

Further Reading:

- EXTON, J.H. (2002). Regulation of phospholipase D. *FEBS Lett.*, **531**, 58–61.
- GODING, J.W., GROBBEN, B. & SLEGGERS, H. (2003). Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. *Biochim Biophys Acta-Mol Basis Dis*, **1638**, 1–19.
- JENKINS, G.M. & FROHMAN, M.A. (2005). Phospholipase D: a lipid centric review. *Cell Mol. Life Sci.*, **62**, 2305–2396.
- KLEIN, J. (2005). Functions and pathophysiological roles of phospholipase D in the brain. *J. Neurochem.*, **94**, 1473–1487.
- LISCOVITCH, M., CZARNY, M., FIUCCI, G. & TANG, X.Q. (2000). Phospholipase D: molecular and cell biology of a novel gene family. *Biochem. J.*, **345**, 401–415.
- MCDERMOTT, M., WAKELAM, M.J. & MORRIS, A.J. (2004). Phospholipase D. *Biochem. Cell. Biol.*, **82**, 225–253.
- POWNER, D.J. & WAKELAM, M.J. (2002). The regulation of phospholipase D by inositol phospholipids and small GTPases. *FEBS Lett.*, **531**, 62–64.
- RIZZO, M.A. & ROMERO, G. (2002). Pharmacological importance of phospholipase D and phosphatidic acid in the regulation of the mitogen-activated protein kinase cascade. *Pharmacol. Ther.*, **94**, 35–50.

References:

- HAMMOND, S.M. *et al.* (1997). *J. Biol. Chem.*, **272**, 3860–3868.
- LIU, Q *et al.* (2002). *Chem. Phys. Lipids*, **115**, 77–84.
- LOPEZ, I *et al.* (1998). *J. Biol. Chem.*, **273**, 12846–12852.
- OKAMOTO, Y *et al.* (2004). *J. Biol. Chem.*, **279**, 5298–5305.
- PETERSEN, G. & HANSEN, H.S. (1999). *FEBS Lett.*, **455**, 41–44.
- RANDALL, R.W. *et al.* (1990). *FEBS Lett.*, **264**, 87–90.
- SARRI, E *et al.* (2003). *Biochem. J.*, **369**, 319–329.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Phosphodiesterases, 3',5'-cyclic nucleotide (E.C.3.1.4.17)

Overview: 3',5'-Cyclic nucleotide phosphodiesterases (PDEs, 3',5'-cyclic-nucleotide 5'-nucleotidohydrolase) catalyse the hydrolysis of a 3',5'-cyclic nucleotide (usually cyclic AMP or cyclic GMP). IBMX is a nonselective inhibitor with an IC₅₀ value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2',3'-cyclic nucleotide 3'-phosphodiesterase (E.C. 3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS.

Nomenclature Other names	PDE1A PDE I	PDE1B PDE I	PDE1C PDE I	PDE2A PDE II, cGMP- stimulated cAMP-PDE, CGS-PDE
Ensembl ID	ENSG00000115252	ENSG00000123360	ENSG00000154678	SwissProt O00408
Rank order of affinity	cGMP > cAMP	cGMP > cAMP	cGMP = cAMP	cAMP >> cGMP
Activators	Ca ²⁺ /CaM	Ca ²⁺ /CaM	Ca ²⁺ /CaM	cGMP
Selective inhibitors	SCH51866 (7.2, Vemulapalli <i>et al.</i> , 1996), vinpocetine (5.1, Loughney <i>et al.</i> , 1996)	SCH51866 (7.2, Vemulapalli <i>et al.</i> , 1996)	SCH51866 (7.2, Vemulapalli <i>et al.</i> , 1996), vinpocetine (4.3, Loughney <i>et al.</i> , 1996)	BAY607550 (8.3–8.8, Boess <i>et al.</i> , 2004), EHNA (5.3, Michie <i>et al.</i> , 1996)

PDE1A, 1B and 1C appear to act as soluble homodimers, while PDE2A is a membrane-bound homodimer. EHNA is also an inhibitor of adenosine deaminase (E.C. 3.5.4.4).

Nomenclature Other names	PDE3A PDE III, cGMP-inhibited cAMP-PDE, CGI-PDE A	PDE3B PDE III, cGMP-inhibited cAMP-PDE, CGI-PDE B
Ensembl ID	ENSG00000172572	ENSG00000152270
Selective inhibitors	Cilostamide (7.5, Sudo <i>et al.</i> , 2000), milrinone (6.3, Sudo <i>et al.</i> , 2000), cGMP	Cilostamide (7.3, Sudo <i>et al.</i> , 2000), milrinone (6.0, Sudo <i>et al.</i> , 2000), cGMP

PDE3A and PDE3B are membrane-bound.

Nomenclature Other names	PDE4A PDE IV	PDE4B PDE IV	PDE4C PDE IV	PDE4D PDE IV
Ensembl ID	ENSG00000065989	ENSG00000184588	ENSG00000105650	ENSG00000113448
Rank order of affinity	cAMP >> cGMP	cAMP >> cGMP	cAMP >> cGMP	cAMP >> cGMP
Activators	—	—	—	PKA-mediated phosphorylation (Houslay & Adams, 2003)
Selective inhibitors	Rolipram (9.0, Wang <i>et al.</i> , 1997), YM976 (8.3, Aoki <i>et al.</i> , 2000), Ro201724 (6.5, Wang <i>et al.</i> , 1997)	Rolipram (9.0, Wang <i>et al.</i> , 1997), Ro201724 (6.4, Wang <i>et al.</i> , 1997)	Rolipram (6.5, Wang <i>et al.</i> , 1997), Ro201724 (5.4, Wang <i>et al.</i> , 1997)	Rolipram (7.2, Wang <i>et al.</i> , 1997), Ro201724 (6.2, Wang <i>et al.</i> , 1997)

PDE4 isoforms are essentially cAMP specific. The potency of YM976 at other members of the PDE4 family has not been reported. PDE4B–D long forms are inhibited by extracellular signal-regulated kinase (ERK)-mediated phosphorylation (Hoffmann *et al.*, 1998; Hoffmann *et al.*, 1999). PDE4A–D splice variants can be membrane-bound or cytosolic (Houslay & Adams, 2003). PDE4 isoforms may be labelled with [³H]-rolipram.

Nomenclature Other names	PDE5A PDE V, cGMP-specific PDE	PDE7A HCP1	PDE7B —	PDE8A High-affinity cAMP-specific and IBMX-insensitive PDE	PDE8B —
Ensembl ID	ENSG00000138735	ENSG00000104732	ENSG00000171408	ENSG00000073417	ENSG00000113231
Rank order of affinity	cGMP > cAMP	cAMP >> cGMP	cAMP >> cGMP	cAMP >> cGMP	cAMP >> cGMP
Activators	PKA (Corbin <i>et al.</i> , 2000), PKG (Corbin <i>et al.</i> , 2000)	—	—	(Fisher <i>et al.</i> , 1998a)	(Hayashi <i>et al.</i> , 1998)
Selective inhibitors	T0156 (9.5, Mochida <i>et al.</i> , 2002), sildenafil (9.0, Turko <i>et al.</i> , 1999), SCH51866 (7.2, Vemulapalli <i>et al.</i> , 1996), zaprinast (6.8, Turko <i>et al.</i> , 1999)	BRL50481 (6.7, Smith <i>et al.</i> , 2004)	Dipyridamole (5.7–6.0, Gardner <i>et al.</i> , 2000; Sasaki <i>et al.</i> , 2000), SCH51866 (5.8, Sasaki <i>et al.</i> , 2000)	Dipyridamole (5.1, Fisher <i>et al.</i> , 1998a)	Dipyridamole (4.3, Hayashi <i>et al.</i> , 1998)

PDE7A appears to be membrane-bound or soluble for PDE7A1 and 7A2 splice variants, respectively. BRL50481 appears not to have been examined as an inhibitor of PDE7B.

Nomenclature Ensembl ID	PDE9A ENSG00000160191	PDE10A ENSG00000112541	PDE11A ENSG00000128655
Substrate specificity	cGMP >> cAMP (Fisher <i>et al.</i> , 1998b)	cAMP, cGMP (Fujishige <i>et al.</i> , 1999)	cAMP, cGMP (Fawcett <i>et al.</i> , 2000)
Selective inhibitors	SCH51866 (5.8, Fisher <i>et al.</i> , 1998b), zaprinast (4.5, Fisher <i>et al.</i> , 1998b)	—	—

Nomenclature Other names	PDE6A cGMP-PDE α , PDE V-b1	PDE6B cGMP-PDE β	PDE6C cGMP-PDE α , PDEA2	PDE6D cGMP-PDE δ	PDE6G cGMP-PDE γ	PDE6H cGMP-PDE γ
Ensembl ID	ENSG00000132915	ENSG00000133256	ENSG00000095464	ENSG00000156973	ENSG00000185527	ENSG00000139053

PDE6 is a membrane-bound tetramer composed of two catalytic chains (PDE6A or PDE6C and PDE6B), an inhibitory chain (PDE6G or PDE6H) and the PDE6D chain. The enzyme is essentially cGMP specific and is activated by the α -subunit of transducin (G_i) and inhibited by sildenafil, zaprinast and dipyrindamole with potencies lower than those observed for PDE5A. Defects in PDE6B are a cause of retinitis pigmentosa and congenital stationary night blindness.

Abbreviations: **BAY607550**, 2-(3,4-dimethoxybenzyl)-7-((1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one; **BRL50481**, 5-nitro-2, N,N-trimethylbenzenesulfonamide; **EHNA**, erythro-9-(2-hydroxy-3-nonyl)adenine; **PKA**, cyclic AMP-dependent protein kinase; **PKG**, cyclic GMP-dependent protein kinase; **Ro201724**, 4-(3-butoxy-4-methoxyphenyl)methyl-2-imidazolidone; **YM976**, (4-[3-chlorophenyl]-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one); **SCH51866**, cis-5,6a,7,8,9,9a-hexahydro-2-(4-[trifluoromethyl]phenylmethyl)-5-methyl-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one

Further Reading:

BANNER, K.H. & TREVETHICK, M.A. (2004). PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. *Trends Pharmacol. Sci.*, **25**, 430–436.

CHUNG, K.F. (2006). Phosphodiesterase inhibitors in airways disease. *Eur. J. Pharmacol.*, **533**, 110–117.

CONTI, M., RICHTER, W., MEHATS, C., LIVERA, G., PARK, J.Y. & JIN, C. (2003). Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. *J. Biol. Chem.*, **278**, 5493–5496.

FELDMAN, A.M. & MCNAMARA, D.M. (2002). Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease. *Clin. Cardiol.*, **25**, 256–262.

GORAYA, T.A. & COOPER, D.M.F. (2005). Ca^{2+} -calmodulin-dependent phosphodiesterase (PDE1): current perspectives. *Cell. Signal.*, **17**, 789–797.

HANING, H., NIEWOHNER, U. & BISCHOFF, E. (2003). Phosphodiesterase type 5 (PDE5) inhibitors. *Prog. Med. Chem.*, **41**, 249–306.

HOUSLAY, M.D. (2005). The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target. *Mol. Pharmacol.*, **68**, 563–567.

HOUSLAY, M.D. & ADAMS, D.R. (2003). PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. *Biochem. J.*, **370**, 1–18.

KUTHE, A., MONTORSI, F., ANDERSSON, K.E. & STIEF, C.G. (2002). Phosphodiesterase inhibitors for the treatment of erectile dysfunction. *Curr. Opin. Invest. Drugs*, **3**, 1489–1495.

LIPWORTH, B.J. (2005). Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. *Lancet*, **365**, 167–175.

MANGANIELLO, V. (2003). Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized. *Mol. Pharmacol.*, **63**, 1209–1211.

MAURICE, D.H., PALMER, D., TILLEY, D.G., DUNKERLEY, H.A., NETHERTON, S.J., RAYMOND, D.R., ELBATARNY, H.S. & JIMMO, S.L. (2003). Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. *Mol. Pharmacol.*, **64**, 533–546.

O'DONNELL, J.M. & ZHANG, H.T. (2004). Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). *Trends Pharmacol. Sci.*, **25**, 158–163.

REFFELMANN, T. & KLONER, R.A. (2003). Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. *Circulation*, **108**, 239–244.

ROTELLA, D.P. (2002). Phosphodiesterase 5 inhibitors: current status and potential applications. *Nat. Rev. Drug Discovery*, **1**, 674–682.

SANZ, M.J., CORTIJO, J. & MORCILLO, E.J. (2005). PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. *Pharmacol. Ther.*, **106**, 269–297.

SHAKUR, Y., HOLST, L.S., LANDSTROM, T.R., MOVSESIAN, M., DEGERMAN, E. & MANGANIELLO, V. (2001). Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. *Prog. Nucleic Acid Res. Mol. Biol.*, **66**, 241–277.

SODERLING, S.H. & BEAVO, J.A. (2000). Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. *Curr. Opin. Cell Biol.*, **12**, 174–179.

References:

- AOKI, M. et al. (2000). *J. Pharmacol. Exp. Ther.*, **295**, 255–260.
- BOESS, F.G. et al. (2004). *Neuropharmacol.*, **47**, 1081–1092.
- CORBIN, J.D. et al. (2000). *Eur. J. Biochem.*, **267**, 2760–2767.
- FAWCETT, L. et al. (2000). *Proc. Natl. Acad. Sci. U.S.A.*, **97**, 3702–3707.
- FISHER, D.A. et al. (1998a). *Biochem. Biophys. Res. Commun.*, **246**, 570–577.
- FISHER, D.A. et al. (1998b). *J. Biol. Chem.*, **273**, 15559–15564.
- FUJISHIGE, K. et al. (1999). *J. Biol. Chem.*, **274**, 18438–18445.
- GARDNER, C. et al. (2000). *Biochem. Biophys. Res. Commun.*, **272**, 186–192.
- HAYASHI, M. et al. (1998). *Biochem. Biophys. Res. Commun.*, **250**, 751–756.
- HOFFMANN, R. et al. (1998). *Biochem. J.*, **333**, 139–149.
- HOFFMANN, R. et al. (1999). *EMBO J.*, **18**, 893–903.
- HOUSLAY, M.D. & ADAMS, D.R. (2003). *Biochem. J.*, **370**, 1–18.
- LOUGHNEY, K. et al. (1996). *J. Biol. Chem.*, **271**, 796–806.
- MICHAELI, T. et al. (1993). *J. Biol. Chem.*, **268**, 12925–12932.
- MICHIE, A.M. et al. (1996). *Cell. Signal.*, **8**, 97–110.
- MOCHIDA, H. et al. (2002). *Eur. J. Pharmacol.*, **456**, 91–98.
- SASAKI, T. et al. (2000). *Biochem. Biophys. Res. Commun.*, **271**, 575–583.
- SMITH, S.J. et al. (2004). *Mol. Pharmacol.*, **66**, 1679–1689.
- SUDO, T. et al. (2000). *Biochem. Pharmacol.*, **59**, 347–356.
- TURKO, I.V. et al. (1999). *Mol. Pharmacol.*, **56**, 124–130.
- VEMULAPALLI, S. et al. (1996). *J. Cardiovasc. Pharmacol.*, **28**, 862–869.
- WANG, P. et al. (1997). *Biochem. Biophys. Res. Commun.*, **234**, 320–324.

ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Phosphoinositide-specific phospholipase C (E.C. 3.1.4.11)

Overview: Phosphoinositide-specific phospholipase C (PLC) catalyses the hydrolysis of phosphatidylinositol (4,5)-bisphosphate to inositol (1,4,5)-trisphosphate and 1,2-diacylglycerol, each of which have major second messenger functions. Two domains, X and Y, essential for catalytic activity, are conserved in the different forms of PLC. Isoforms of PLC- β (ENSF00000000466) are activated primarily by 7TM receptors through members of the $G_{q/11}$ family of G proteins. The receptor-mediated activation of PLC- γ involves their phosphorylation by tyrosine kinases in response to activation of a variety of growth factor receptors and immune system receptors. PLC- ϵ 1 may represent a point of convergence of signalling via both 7TM and catalytic receptors. Ca^{2+} ions are required for catalytic activity of PLC isoforms and have been suggested to be the major physiological form of regulation of PLC- δ activity. PLC has been suggested to be activated non-selectively by the small molecule *m*-3M3FBS (Bae *et al.*, 2003), although this mechanism of action has been questioned (Krjukova *et al.*, 2004). The aminosteroid U73122 has been described as an inhibitor of phosphoinositide-specific PLC (Smith *et al.*, 1990), although its selectivity among the isoforms is untested and it has been reported to occupy the H_1 histamine receptor (Hughes *et al.*, 2000).

Nomenclature	β 1	β 2	β 3	β 4
Other names	PLC-I, PLC-154, KIAA0581	—	—	—
Ensembl ID	ENSG00000182621	ENSG00000137841	ENSG00000149782	ENSG00000101333
Endogenous activators	Gzq (Smrcka <i>et al.</i> , 1991; Hepler <i>et al.</i> , 1993), Gz11 (Hepler <i>et al.</i> , 1993), G $\beta\gamma$ (Park <i>et al.</i> , 1993)	Gz16 (Lee <i>et al.</i> , 1992), G $\beta\gamma$ (Camps <i>et al.</i> , 1992; Park <i>et al.</i> , 1993)	Gzq (Lee <i>et al.</i> , 1992), G $\beta\gamma$ (Carozzi <i>et al.</i> , 1993; Park <i>et al.</i> , 1993)	Gzq (Jhon <i>et al.</i> , 1993)

Nomenclature	γ 1	γ 2	δ 1	δ 3	δ 4
Other names	PLC-II, PLC-148	PLC-IV	PLC-III	—	—
Ensembl ID	ENSG00000124181	ENSG00000197943	ENSG00000187091	ENSG00000161714	ENSG00000115556
Endogenous activators	PtdIns(3,4,5) P_3 (Bae <i>et al.</i> , 1998)	PtdIns(3,4,5) P_3 (Bae <i>et al.</i> , 1998)	Transglutaminase II (Murthy <i>et al.</i> , 1999), p122-RhoGAP (Homma & Emori, 1995), spermine (Haber <i>et al.</i> , 1991), G $\beta\gamma$ (Park <i>et al.</i> , 1993)	—	—
Inhibitors	—	—	Sphingomyelin (Pawelczyk & Lowenstein, 1992)	—	—

PLC- δ 2 has been cloned from bovine sources (Meldrum *et al.*, 1991).

Nomenclature	ϵ 1	ζ 1	η 1	η 2
Other names	Pancreas-enriched PLC	—	—	—
Ensembl/GenBank ID	ENSG00000138193	ENSG00000139151	AY691170 (Hwang <i>et al.</i> , 2005)	DQ176850 (Zhou <i>et al.</i> , 2005)
Endogenous activators	Ras (Song <i>et al.</i> , 2001), Rho (Wing <i>et al.</i> , 2003)	—	—	G $\beta\gamma$ (Zhou <i>et al.</i> , 2005)

A series of PLC-like proteins (PLCL1 ENSG00000115896; PLCL2 ENSG00000154822 and PLCL3 ENSG00000114805) form a family (ENSF00000000386) with PLC δ and PLC ζ 1 isoforms, but appear to lack catalytic activity.

Abbreviations: *m*-3M3FBS, 2,4,6-trimethyl-*N*-(*meta*-3-trifluoromethylphenyl)-benzenesulphonamide; PtdIns (3,4,5) P_3 , phosphatidylinositol (3,4,5)-trisphosphate; U73122, 1-(6-[(17 β)-3-methoxyestra-1,3,5[10]-trien-17-yl]amino]hexyl)-1*H*-pyrrole-2,5-dione

Further Reading:

- FUKAMI, K. (2002). Structure, regulation, and function of phospholipase C isozymes. *J. Biochem.*, **131**, 293–299.
- IRVINE, R.F. (2003). Nuclear lipid signalling. *Nat. Rev. Mol. Cell. Biol.*, **4**, 349–360.
- NAHORSKI, S.R., YOUNG, K.W., CHALLISS, R.A.J. & NASH, M.S. (2003). Visualizing phosphoinositide signalling in single neurons gets a green light. *Trends Neurosci.*, **26**, 444–452.
- PHILIP, F., GUO, Y. & SCARLATA, S. (2002). Multiple roles of pleckstrin homology domains in phospholipase C β function. *FEBS Lett.*, **531**, 28–32.
- REBECCHI, M.J. & PENTYALA, S.N. (2000). Structure, function, and control of phosphoinositide-specific phospholipase C. *Physiol. Rev.*, **80**, 1291–1335.
- RHEE, S.G. (2001). Regulation of phosphoinositide-specific phospholipase C. *Annu. Rev. Biochem.*, **70**, 281–312.
- WILDE, J.I. & WATSON, S.P. (2001). Regulation of phospholipase C γ isoforms in haematopoietic cells: why one, not the other? *Cell. Signal.*, **13**, 691–701.
- WING, M.R., BOURDON, D.M. & HARDEN, T.K. (2003). PLC- ϵ : a shared effector protein in Ras-, Rho-, and G $\alpha\beta\gamma$ -mediated signaling. *Mol. Interv.*, **3**, 273–280.

References:

- BAE, Y.S. *et al.* (1998). *J. Biol. Chem.*, **273**, 4465–4469.
- BAE, Y.S. *et al.* (2003). *Mol. Pharmacol.*, **63**, 1043.
- CAMPS, M. *et al.* (1992). *Nature*, **360**, 684–686.
- CAROZZI, A. *et al.* (1993). *FEBS Lett.*, **315**, 340–342.
- GHOSH, S. *et al.* (1997). *Protein Expr. Purif.*, **9**, 262–278.
- HABER, M.T. *et al.* (1991). *Arch. Biochem. Biophys.*, **288**, 243–249.
- HEPLER, J.R. *et al.* (1993). *J. Biol. Chem.*, **268**, 14367–14375.
- HOMMA, Y. & EMORI, Y. (1995). *EMBO J.*, **14**, 286–291.
- HUGHES, S.A. *et al.* (2000). *Naunyn-Schmiedeberg's Arch. Pharmacol.*, **362**, 555–558.
- HWANG, J.I. *et al.* (2005). *Biochem. J.*, **389**, 181–186.

- JHON, D.-Y. *et al.* (1993). *J. Biol. Chem.*, **268**, 6654–6661.
- KELLEY, G.G. *et al.* (2001). *EMBO J.*, **20**, 743–754.
- KOHNO, T. *et al.* (1995). *Hum. Mol. Genet.*, **4**, 667–674.
- KRJUKOVA, J. *et al.* (2004). *Br. J. Pharmacol.*, **143**, 3–7.
- LEE, C.H. *et al.* (1992). *J. Biol. Chem.*, **267**, 16044–16047.
- LOPEZ, I. *et al.* (2001). *J. Biol. Chem.*, **276**, 2758–2765.
- MELDRUM, E. *et al.* (1991). *Eur. J. Biochem.*, **196**, 159–165.
- MURTHY, S.N.P. *et al.* (1999). *Proc. Natl. Acad. Sci. U.S.A.*, **96**, 11815–11819.
- PARK, D. *et al.* (1993). *J. Biol. Chem.*, **268**, 4573–4576.
- PAWELCZYK, T. & LOWENSTEIN, J.M. (1992). *Arch. Biochem. Biophys.*, **297**, 328–333.
- SMITH, R.J. *et al.* (1990). *J. Pharmacol. Exp. Ther.*, **253**, 688–697.
- SMRCKA, A.V. *et al.* (1991). *Science*, **251**, 804–807.
- SONG, C. *et al.* (2001). *J. Biol. Chem.*, **276**, 2752–2757.
- WING, M.R. *et al.* (2003). *Mol. Interv.*, **3**, 273–280.
- ZHOU, Y. *et al.* (2005). *Biochem. J.*, **391**, 667–676.
- ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.

Soluble guanylyl cyclase (E.C. 4.6.1.2)

Overview: Soluble guanylyl cyclase (GTP diphosphate-lyase (cyclising)) is a heterodimer comprising α and β chains, both of which have two subtypes in man (predominantly $\alpha 1\beta 1$; see Zabel *et al.*, 1998). A haem group is associated with the β chain and is the target for the endogenous ligand nitric oxide (NO $\bullet$), and, potentially, carbon monoxide (Friebe *et al.*, 1996). The enzyme converts guanosine-5'-triphosphate (GTP) to the intracellular second messenger 3',5'-guanosine monophosphate (cGMP).

Nomenclature	Soluble guanylyl cyclase
Preferred abbreviation	sGC
Ensembl ID	$\alpha 1$ ENSG00000164116; $\alpha 2$ ENSG00000152402; $\beta 1$ ENSG00000061918; $\beta 2$ ENSG00000123201
Selective activators	NO $\bullet$, YC1 (Friebe <i>et al.</i> , 1996), BAY412272 (Stasch <i>et al.</i> , 2001), BAY582667 (Stasch <i>et al.</i> , 2002)
Selective inhibitors	ODQ (7.5; Garthwaite <i>et al.</i> , 1995)

ODQ also shows activity at other haem-containing proteins (Feelisch *et al.*, 1999), while YC1 may also inhibit cGMP-hydrolysing phosphodiesterases (Friebe *et al.* 1998).

Abbreviations: **BAY412272**, 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1*H*-pyrazolo[3,4-*b*]pyridin-3-yl]-pyrimidin-4-ylamine); **BAY582667**, 4-([4-carboxybutyl][2-{(4-phenethylbenzyl)oxy}phenethyl]amino)methyl(benzoic)acid; **ODQ**, 1*H*-[1,2,4]oxadiazolo[4,3-*a*]quinoxalin-1-one; **YC1**, 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole HMR1766

Further Reading:

- DAVIS, K.L., MARTIN, E., TURKO, I.V. & MURAD, F. (2001). Novel effects of nitric oxide. *Annu. Rev. Pharmacol. Toxicol.*, **41**, 203–236.
- DENNINGER, J.W. & MARLETTA, M.A. (1999). Guanylate cyclase and the NO/cGMP signaling pathway. *Biochim. Biophys. Acta – Bioenergetics*, **1411**, 334–350.
- FRIEBE, A. & KOESLING, D. (2003). Regulation of nitric oxide-sensitive guanylyl cyclase. *Circ. Res.*, **93**, 96–105.
- HOBBS, A.J. (1997). Soluble guanylate cyclase: the forgotten sibling. *Trends Pharmacol. Sci.*, **18**, 484–491.
- KOESLING, D. & FRIEBE, A. (1999). Soluble guanylyl cyclase: structure and regulation. *Rev. Physiol. Biochem. Pharmacol.*, **135**, 41–65.
- LUCAS, K.A., PITARI, G.M., KAZEROUNIAN, S., RUIZ-STEWART, I., PARK, J., SCHULZ, S., CHEPENIK, K.P. & WALDMAN, S.A. (2000). Guanylyl cyclases and signaling by cyclic GMP. *Pharmacol. Rev.*, **52**, 375–414.
- PYRIOCHOU, A. & PAPAPETROPOULOS, A. (2005). Soluble guanylyl cyclase: more secrets revealed. *Cell. Signal.*, **17**, 407–413.
- SITARAMAYYA, A. (2002). Soluble guanylate cyclases in the retina. *Mol. Cell. Biochem.*, **230**, 177–186.
- ZABEL, U., WEEGER, M., LA, M. & SCHMIDT, H.H.H.W. (1998). Human soluble guanylate cyclase: functional expression and revised isoenzyme family. *Biochem. J.*, **335**, 51–57.

References:

- FEELISCH, M. *et al.* (1999). *Mol. Pharmacol.*, **56**, 243–253.
- FRIEBE, A. *et al.* (1996). *EMBO J.*, **15**, 6863–6868.
- FRIEBE, A. *et al.* (1998). *Mol. Pharmacol.*, **54**, 962–967.
- GARTHWAITE, J. *et al.* (1995). *Mol. Pharmacol.*, **48**, 184–188.
- STASCH, J.P. *et al.* (2001). *Nature*, **410**, 212–215.
- STASCH, J.P. *et al.* (2002). *Br. J. Pharmacol.*, **136**, 773–783.
- ALEXANDER, S.P.H., MATHIE, A. & PETERS, J.A. (2007). Guide to Receptors and Channels (GRAC), 2nd edition (2007 revision). *Br. J. Pharmacol.*, **150** (Suppl. 1), S1–S168.